This can include a risk of seizures, suicidal ideation, abuse, and dependence
(1) Controlled-Release PHEN/TPM in Severely Obese Adults (EQUIP) trial (obesity without comorbidities), (2) Controlled-Release Phentermine plus Topiramate Combination in Overweight and Obese Adults (CONQUER) trial (obesity with comorbidities), and (3) SEQUEL (2-year extension of CONQUER), were comprised of 7% of older adult participants across the trials, although the upper age limit was 70 [111,112,113]
Theres a rationale behind the preference, at least on paper
The obesity trial studied a substantially heavier population, while lean-recomposition reports describe a lighter one
Conjugating palmitate into the liposomal lipid layer significantly affected drug encapsulation